Leflunomide-associated pancytopenia with or without methotrexate

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1206-1211

  Chan, Jonathan ^a   Sanders, Daniela C ^b   Du, Leanne ^b   Pillans, Peter I ^a,b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c Clinical Pharmacology ^*  (Australia)

Author keywords

Leflunomide; Methotrexate; Pancytopenia

Indexed keywords

HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ARTICLE; AUSTRALIA; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DEATH; DEHYDRATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FATALITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; LYMPHOCYTE; MALE; MONITORING; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; SORE THROAT; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; PANCYTOPENIA;

EID: 3042550512     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E012     Document Type: Article

References (18)

1. Product monograph. Arava (leflunomide). Lane Cove, New South Wales, Australia: Aventis Pharma, June 2003. 27th MIMS Annual Edition, MediMedia Australia, New South Wales.
2. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
3. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. and the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicenter trial. Lancet 1999;353:259-66.
4. Weinblatt MR, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
5. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
6. Fox RI, Herrmann ML, Costakis GF, Wahl GM, Morris RE, Strand V, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93:198-208.
7. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by an immunomodulatory agent leflunomide. Biochem Pharmacol 1995;50:861-7.
8. Goldernberg MM. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Clin Ther 1999;21:1837-52.
9. Adverse Drug Reactions Advisory Committee (ADRAC). Leflunomide: serious hepatic, blood, skin and respiratory reactions. Aust Adverse Drug React Bull 2001;20(2):7.
10. Hill RL, Topliss DJ, Purcell PM. Pancytopenia associated with leflunomide and methotrexate (letter). Ann Pharmacother 2003;37:149. DOI 10.1345/aph.1C293
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
12. European Agency for the Evaluation of Medicinal Products. EMEA public statement on leflunomide (Arava): pancytopenia and serious skin reactions, Oct 1999 [doc ref EMEA/31637/99]. www.emea.eu.int/htms/human/ drugalert/drugalert. htm (accessed 2003 Oct 12).
13. Siva C, Eisen AS, Shepherd R, Cunninghad F, Fang MA, Finch W, et al. Leflunomide use during the first 33 months after Food and Drug Administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum 2003;49:745-51.
14. Auer J, Hinterreiter M, Allinger S, Kirchgatterer A, Knoflach P. Severe pancytopenia after leflunomide in rheumatoid arthritis. Acta Med Austriaca 2000;27:131-2.
15. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999;58:1137-64.
16. Loorand-Stiver L, Murty M. Leflumonide (Arava): hematological, hepatic and respiratory reactions. Canadian adverse drug reaction newsletter. Oct 2002;12(4):2-3.
17. Food and Drug Administration. Arava (leflunomide). Medwatch-2003 safety alerts for drugs, biologics, medical devices, and dietary supplements. Nov 2003. www.fda.gov/medwatch/SAFETY/2003/safety03. htm#arava (accessed 2003 Oct 15).
18. Mofredj A, Baraka D, Charoud A. Comment: severe pancytopenia associated with methotrexate therapy for rheumatoid arthritis (letter). Ann Pharmacother 2002;36:1295. DOI 10.1345/aph.1A052a